HC Wainwright Analysts Lower Earnings Estimates for MLYS

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities research analysts at HC Wainwright lowered their FY2030 earnings estimates for shares of Mineralys Therapeutics in a report issued on Wednesday, August 12th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of $3.41 for the year, down from their prior estimate of $3.73. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($2.30) per share.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30).

Several other analysts have also recently issued reports on the company. Jefferies Financial Group reiterated a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. TD Cowen assumed coverage on shares of Mineralys Therapeutics in a report on Monday, April 27th. They issued a “buy” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen downgraded shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

Mineralys Therapeutics Price Performance

Shares of NASDAQ:MLYS opened at $27.05 on Thursday. Mineralys Therapeutics has a 1 year low of $12.59 and a 1 year high of $47.65. The firm’s 50-day moving average is $26.42 and its two-hundred day moving average is $27.60. The firm has a market capitalization of $2.23 billion, a PE ratio of -6.38 and a beta of 0.68.

Hedge Funds Weigh In On Mineralys Therapeutics

Several hedge funds have recently bought and sold shares of the company. Navalign LLC purchased a new stake in Mineralys Therapeutics during the fourth quarter worth $33,000. KBC Group NV acquired a new stake in Mineralys Therapeutics in the first quarter valued at $33,000. Royal Bank of Canada increased its position in shares of Mineralys Therapeutics by 262.3% in the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after buying an additional 1,107 shares in the last quarter. FNY Investment Advisers LLC raised its stake in shares of Mineralys Therapeutics by 400.0% during the 2nd quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company’s stock worth $67,000 after buying an additional 2,000 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Mineralys Therapeutics by 1,845.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock worth $76,000 after buying an additional 1,993 shares during the last quarter. 84.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, CEO Jon Congleton sold 75,000 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total value of $1,960,500.00. Following the completion of the transaction, the chief executive officer directly owned 614,321 shares of the company’s stock, valued at approximately $16,058,350.94. This trade represents a 10.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.09, for a total transaction of $58,785.30. Following the sale, the insider owned 51,384 shares of the company’s stock, valued at approximately $1,391,992.56. The trade was a 4.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 217,313 shares of company stock valued at $5,624,488 over the last 90 days. Company insiders own 18.94% of the company’s stock.

Mineralys Therapeutics News Roundup

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Regulatory milestone remains on track: The company reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational treatment for hypertension, and said commercial launch preparations are progressing in anticipation of approval. Mineralys second-quarter results and corporate update
• Positive Sentiment: Financial flexibility improved: Management highlighted a strong cash position with funding expected to support operations into 2028. Strategic financing initiatives and the repurchase of the Tanabe royalty obligation also strengthen the long-term economics of lorundrostat by reducing a future royalty burden. Mineralys launch readiness and cash runway
• Positive Sentiment: New medical leadership: Mineralys appointed cardiovascular medicine executive Dr. Terry Ferguson as chief medical officer. He will oversee medical strategy and late-stage clinical activities ahead of the potential lorundrostat launch. Mineralys appoints chief medical officer
• Neutral Sentiment: Short-interest data offered little signal: Reported short interest was zero shares, with a zero-day days-to-cover ratio, suggesting the data does not indicate meaningful short-selling pressure.
• Negative Sentiment: Quarterly loss missed expectations sharply: Mineralys reported a second-quarter loss of $2.85 per share, compared with the analyst consensus estimate of a $0.55 loss. The sizable variance may be weighing on the stock, although the company remains focused on its pre-commercial development and launch activities. Mineralys second-quarter earnings call transcript

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.